Compositions and methods of treating tumors
AssigneeThe Trustees of the University of Pennsylvania
InventorsMark I. Greene, Donald M. O'Rourke, Ramachandran Murali, Byeong-Woo Park
Life of this patent
Estimating the term…
Abstract
Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise adminstering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.
Claims25
A method of treating an individual who has an erbB protein mediated tumor comprising the steps of:
- administering to said individual a nucleic acid molecule that encodes a protein that dimerizes with said erbB protein and that is deficient in tyrosine kinase activity, and
- exposing said individual to a therapeutically effective amount of anti-cancer radiation and/or administering to said individual a therapeutically effective amount of an anti-cancer chemotherapeutic.
A method of treating an individual who has an erbB protein mediated brain tumor comprising the step of:
- administering to said individual a nucleic acid molecule that encodes a protein that dimerizes with said erbB protein and is deficient in tyrosine kinase activity.
The method of claim 14 wherein said individual is exposed to a therapeutically effective amount of anti-cancer radiation and/or administered a therapeutically effective amount of an anti-cancer chemotherapeutic.
A method of inhibiting proliferation of a mutant EGFR-mediated tumor cell comprising the step of delivering to said cell a nucleic acid molecule that encodes a protein that dimerizes with mutant EGFR and is deficient in tyrosine kinase activity.
A method of treating an individual who has an erbB protein mediated tumor comprising the steps of:
- administering to said individual a composition which inhibits formation of erbB protein dimers that produce elevated tyrosine kinase activity in a tumor cell, and
- exposing said individual to a therapeutically effective amount of anti-cancer radiation.
A method of treating an individual who has a tumor, wherein said tumor is characterized by tumor cells that have multimeric receptor ensembles which provide kinase activity associated with a transformed phenotype, said method comprising the steps of:
- a) administering to the individual, a composition that disrupts the kinase activity associated with the multimeric receptor ensemble;
- and
- b) exposing the individual to a therapeutic amount of gamma radiation.
A method of treating an individual who has a tumor, wherein said tumor is characterized by tumor cells that have multimeric receptor ensembles which provide kinase activity associated with a transformed phenotype, said method comprising the steps of:
- a) administering to the individual, a peptide, non-proteinaceous compound or nucleic acid molecules that encodes a protein that disrupts the kinase activity associated with the multimeric receptor ensemble;
- and
- b) exposing the individual to a therapeutic amount of gamma radiation and/or administering a therapeutic amount of a cytotoxic chemotherapeutic agent to said individual.
A method of treating an individual who has a tumor, wherein said tumor is characterized by tumor cells that comprise an EGFR species, said method comprising the steps of:
- a) administering to the individual, a composition that disrupts kinase activity mediated by an EGFR species;
- and
- b) exposing the individual to a therapeutic amount of gamma radiation and/or administering a therapeutic amount of a cytotoxic chemotherapeutic agent to said individual.
Dependencies are inferred from the claim text.